Cheadle Royal-based Alderley Lighthouse Labs has signed an agreement with PinPoint Data Science to offer the PinPoint Test, a blood test for cancer risk assessment, to the public.
Under the agreement, Alderley Lighthouse Labs will become the first private laboratory in the UK to offer the PinPoint Test, the company said.
The two companies said the deal brings together laboratory expertise and artificial intelligence (AI) technology in blood-based cancer risk assessment.
They described the agreement as reflecting a shared commitment to diagnostic technologies that help patients gain earlier insights into their health and support timely clinical assessment.
PinPoint Data Science is a UK-based developer of AI-driven diagnostic software.
Its flagship product, the PinPoint Test, applies machine learning techniques to biomarker analysis and combines cancer-related signals in the blood to give an aggregated assessment of cancer risk when symptoms first appear.
PinPoint is a Leeds-based MedTech company. The test was developed over 10 years in the NHS with data from almost 400,000 patients.
Alderley Lighthouse Labs provides pathology services to both the private healthcare sector and the NHS.
The laboratory said the agreement builds on its ambition to expand its diagnostic services through collaboration with technology partners.
For PinPoint, the companies said, the agreement is a first step from its development work in the NHS to making the test available more widely in the private sector.
Giles Tully, CEO of PinPoint Data Science, said: “In Alderley Lighthouse Labs, we have found a partner that shares our vision for a future where AI-enabled technologies can enhance and improve routine diagnostics. After 10 years of development and validation work in the NHS, this agreement means that together we can bring PinPoint blood tests for cancer risk assessment directly to UK consumers for the first time.”
Mark Wigglesworth, CEO of Alderley Lighthouse Labs, said: “We are excited to be partnering with PinPoint Data Science to bring this innovative technology into clinical practice, advancing the future of diagnostics and helping patients access timely assessment, clearer clinical insights and more effective pathways to diagnosis and treatment.”
Further details about the launch, availability and routes for accessing the PinPoint Test will be announced in due course.
In June 2024 Maven VCTs invested in Alderley Lighthouse Labs.